PE20231652A1 - Nuevo inhibidor de la secrecion de acido y uso del mismo - Google Patents

Nuevo inhibidor de la secrecion de acido y uso del mismo

Info

Publication number
PE20231652A1
PE20231652A1 PE2022002955A PE2022002955A PE20231652A1 PE 20231652 A1 PE20231652 A1 PE 20231652A1 PE 2022002955 A PE2022002955 A PE 2022002955A PE 2022002955 A PE2022002955 A PE 2022002955A PE 20231652 A1 PE20231652 A1 PE 20231652A1
Authority
PE
Peru
Prior art keywords
compound
acid secretion
same
new inhibitor
alkyl
Prior art date
Application number
PE2022002955A
Other languages
English (en)
Inventor
Hong Chul Yoon
Joon Tae Park
Jung Woo Lee
Kyung Mi An
A Rang Im
Woo Jin Jeon
Jae Ho Heo
Chang Hee Hong
Jung Eun Park
Te Ik Sohn
Da Hae Hong
Jung Ho Kim
Jae Eui Shin
Yeong Ran Yoo
Min Whan Chang
In Gyu Je
Su Yeon Kang
Yoon Sung Song
Joo Yun Lee
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of PE20231652A1 publication Critical patent/PE20231652A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Referido a un compuesto de formula II, o una sal farmaceuticamente aceptable del mismo, en donde X1 es F; X2 es H o F; R1 es metilo o etilo; y R2 es -O(alquilo C1-C4) o -(alquilo C1-C4). En donde un compuesto seleccionado es 1-(5-(2-fluorofenil)-4-metoxi-1-((6-metoxipiridin-3-il)sulfonil)-1H-pirrol-3-il)-N-metilmetanamina. Este compuesto es inhibidor de la secrecion de acido. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto o una sal farmaceuticamente aceptable del mismo y su uso en la prevencion o tratamiento de ulceras gastrointestinales o enfermedades relacionadas con el acido gastrico.
PE2022002955A 2020-06-17 2021-06-16 Nuevo inhibidor de la secrecion de acido y uso del mismo PE20231652A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200073900 2020-06-17
PCT/KR2021/007572 WO2021256861A1 (ko) 2020-06-17 2021-06-16 신규한 산 분비 억제제 및 이의 용도

Publications (1)

Publication Number Publication Date
PE20231652A1 true PE20231652A1 (es) 2023-10-17

Family

ID=79176045

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002955A PE20231652A1 (es) 2020-06-17 2021-06-16 Nuevo inhibidor de la secrecion de acido y uso del mismo

Country Status (16)

Country Link
US (2) US11767311B2 (es)
EP (1) EP4148050A4 (es)
JP (1) JP7404561B2 (es)
KR (2) KR20210156235A (es)
CN (1) CN115884968B (es)
AU (1) AU2021293694B2 (es)
BR (1) BR112022025613A2 (es)
CA (1) CA3182882A1 (es)
CL (1) CL2022003601A1 (es)
CO (1) CO2023000396A2 (es)
DO (1) DOP2022000291A (es)
EC (1) ECSP23002606A (es)
MX (1) MX2022016515A (es)
PE (1) PE20231652A1 (es)
TW (1) TWI797645B (es)
WO (1) WO2021256861A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210156235A (ko) 2020-06-17 2021-12-24 일동제약(주) 신규한 산 분비 억제제 및 이의 용도
KR20230091056A (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
WO2023113474A1 (ko) * 2021-12-15 2023-06-22 일동제약(주) 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
KR20230102353A (ko) * 2021-12-30 2023-07-07 주식회사 대웅제약 삼중음성유방암의 예방 또는 치료용 약학적 조성물
CN114539219A (zh) * 2022-03-17 2022-05-27 日照正济药业有限公司 一种富马酸伏诺拉生的制备方法
WO2023211843A1 (en) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions
TW202411216A (zh) * 2022-05-23 2024-03-16 南韓商日東製藥股份有限公司 ６－甲氧基吡啶－３－基衍生物之製造方法
TW202411215A (zh) * 2022-05-23 2024-03-16 南韓商日東製藥股份有限公司 ６－甲氧基吡啶－３－基衍生物之製造方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437642T1 (de) * 2002-06-14 2009-08-15 Takeda Pharmaceutical Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ES2402362T3 (es) * 2004-09-30 2013-05-03 Takeda Pharmaceutical Company Limited Inhibidores de la bomba de protones
SI2327692T1 (sl) * 2005-08-30 2012-11-30 Tekeda Pharmaceutical Company Ltd heterociklilsulfonil aminometil hetero arilno substituirani H pirolni derivati kot inhibitorji izločanja kisline
WO2007114338A1 (ja) * 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited 酸分泌抑制薬
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
US8969387B2 (en) * 2008-08-27 2015-03-03 Takeda Pharmaceutical Company Limited Pyrrole compounds
US8895588B2 (en) * 2009-03-26 2014-11-25 Takeda Pharmaceutical Company Limited Pyrazole compound
SG11201408511QA (en) * 2012-06-27 2015-01-29 Takeda Pharmaceutical Liquid preparations of amines and organic acids stabilized by salts
CN105143187B (zh) 2013-02-28 2018-04-03 武田药品工业株式会社 制备磺酰氯化合物的方法
CN105693693A (zh) * 2014-11-27 2016-06-22 江苏柯菲平医药股份有限公司 一种吡咯类胃酸分泌和抑制剂化合物盐的制备
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN106432191A (zh) * 2015-08-10 2017-02-22 陕西合成药业股份有限公司 一种新的吡咯类衍生物、其制备方法及其在医药上的应用
KR20170113040A (ko) 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
CN109843869B (zh) * 2016-09-29 2021-07-16 江苏吉贝尔药业股份有限公司 1-[(吡啶-3-基-磺酰基)-1h-吡咯-3-基]甲胺衍生物及其药物组合物和用途
WO2019013310A1 (en) 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited PREPARATION COMPRISING VONOPRAZAN
CN110396080B (zh) * 2018-04-24 2022-07-08 广东东阳光药业有限公司 一种富马酸沃诺拉赞代谢物及其氘代物的制备方法
CN108558831B (zh) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
KR20210156235A (ko) 2020-06-17 2021-12-24 일동제약(주) 신규한 산 분비 억제제 및 이의 용도
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CA3182882A1 (en) 2021-12-23
TW202325702A (zh) 2023-07-01
CN115884968B (zh) 2024-06-21
ECSP23002606A (es) 2023-03-31
MX2022016515A (es) 2023-01-30
EP4148050A1 (en) 2023-03-15
TW202214588A (zh) 2022-04-16
KR102432523B1 (ko) 2022-08-16
BR112022025613A2 (pt) 2023-01-17
TWI797645B (zh) 2023-04-01
EP4148050A4 (en) 2023-10-25
JP2023524172A (ja) 2023-06-08
AU2021293694A1 (en) 2023-01-19
AU2021293694B2 (en) 2023-12-21
US20230373954A1 (en) 2023-11-23
CL2022003601A1 (es) 2023-07-07
US20230192650A1 (en) 2023-06-22
WO2021256861A1 (ko) 2021-12-23
KR20210156234A (ko) 2021-12-24
CN115884968A (zh) 2023-03-31
US11767311B2 (en) 2023-09-26
DOP2022000291A (es) 2023-01-15
JP7404561B2 (ja) 2023-12-25
KR20210156235A (ko) 2021-12-24
CO2023000396A2 (es) 2023-02-27

Similar Documents

Publication Publication Date Title
PE20231652A1 (es) Nuevo inhibidor de la secrecion de acido y uso del mismo
MX2009000871A (es) Novedosos inhibidores de transcriptasa inversa de vih.
PE20080706A1 (es) Arilmidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
AR086254A1 (es) Derivados de imidazol utiles para el tratamiento de artritis
AR115949A1 (es) Compuestos heterocíclicos
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
EA201171213A1 (ru) Ингибитор р38 мар киназы
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
NO20053398D0 (no) Farmasoytiske preparater av sertaconazol for vaginal anvendelse.
AR057162A1 (es) Compuestos de benzamida como inhibidores de la enzima histona desacetilasa (hdac)
PE20060823A1 (es) Compuestos de arilsulfonamida como moduladores de receptores cck1/cck2
CO5611172A2 (es) Stents recubiertos con n-{5-[4-(4-metil-piperazino-metil) -benozilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina
AR051797A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
ECSP088965A (es) Derivados de 2-tioxantina que actúan como inhibidores de la mpo
AR071049A1 (es) Uso de n- fenilamidas de acido 2- sulfonilaminobenzoidco sustituidas con sulfonilo en el tratamiento del dolor
PE20212323A1 (es) Formulaciones farmaceuticas
GEP20227388B (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
PE20060696A1 (es) Inhibidores de la adenilato ciclasa soluble
PE20060416A1 (es) Composicion de inhibidores de renina e inhibidores de proteinas de efusion
PE20221630A1 (es) Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
BRPI0918966A8 (pt) composto inibidor de proteases, composição farmacêutica compreendendo dito compostos e uso terapêutico do mesmo
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
PE20210158A1 (es) Composiciones y metodos para tratar el estrenimiento grave
El Bialy et al. Current progress in antifibrotics